Top

Published in:

01-01-2013 | Educational Series – Blue Series

Next-generation sequencing reveals the secrets of the chronic lymphocytic leukemia genome

Authors: Andrew J. Ramsay, Alejandra Martínez-Trillos, Pedro Jares, David Rodríguez, Agnieszka Kwarciak, Víctor Quesada

Published in: Clinical and Translational Oncology | Issue 1/2013

Abstract

The study of the detailed molecular history of cancer development is one of the most promising techniques to understand and fight this diverse and prevalent disease. Unfortunately, this history is as diverse as cancer itself. Therefore, even with next-generation sequencing techniques, it is not easy to distinguish significant (driver) from random (passenger) events. The International Cancer Genome Consortium (ICGC) was formed to solve this fundamental issue by coordinating the sequencing of samples from 50 different cancer types and/or sub-types that are of clinical and societal importance. The contribution of Spain in this consortium has been focused on chronic lymphocytic leukemia (CLL). This approach has unveiled new and unexpected events in the development of CLL. In this review, we introduce the approaches utilized by the consortium for the study of the CLL genome and discuss the recent results and future perspectives of this work.

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 5:646–674CrossRef

Stratton MR, Campbell PJ, Futreal PA (2009) The cancer genome. Nature 7239:719–724CrossRef

Greenman C, Stephens P, Smith R et al (2007) Patterns of somatic mutation in human cancer genomes. Nature 7132:153–158CrossRef

Bozic I, Antal T, Ohtsuki H et al (2010) Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci USA 43:18545–18550CrossRef

Hudson TJ, Anderson W, Artez A et al (2010) International network of cancer genome projects. Nature 7291:993–998CrossRef

Zhao J, Grant SF (2011) Advances in whole genome sequencing technology. Curr Pharm Biotechnol 2:293–305CrossRef

Meyerson M, Gabriel S, Getz G (2010) Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 10:685–696CrossRef

Ley TJ, Mardis ER, Ding L et al (2008) DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 7218:66–72CrossRef

Campbell PJ, Stephens PJ, Pleasance ED et al (2008) Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet 6:722–729CrossRef

10.

Chapman MA, Lawrence MS, Keats JJ et al (2011) Initial genome sequencing and analysis of multiple myeloma. Nature 7339:467–472CrossRef

11.

Stephens PJ, McBride DJ, Lin ML et al (2009) Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 7276:1005–1010CrossRef

12.

Pleasance ED, Cheetham RK, Stephens PJ et al (2010) A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 7278:191–196CrossRef

13.

Campbell PJ, Yachida S, Mudie LJ et al (2010) The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 7319:1109–1113CrossRef

14.

Totoki Y, Tatsuno K, Yamamoto S et al (2011) High-resolution characterization of a hepatocellular carcinoma genome. Nat Genet 5:464–469CrossRef

15.

Parsons DW, Li M, Zhang X et al (2011) The genetic landscape of the childhood cancer medulloblastoma. Science 6016:435–439CrossRef

16.

Berger MF, Lawrence MS, Demichelis F et al (2011) The genomic complexity of primary human prostate cancer. Nature 7333:214–220CrossRef

17.

Welch JS, Westervelt P, Ding L et al (2011) Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA 15:1577–1584CrossRef

18.

Wu G, Broniscer A, McEachron TA et al (2012) Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 3:251–253CrossRef

19.

Network CGAR (2011) Integrated genomic analyses of ovarian carcinoma. Nature 7353:609–615

20.

Puente XS, Pinyol M, Quesada V et al (2011) Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 7354:101–105CrossRef

21.

Quesada V, Conde L, Villamor N et al (2012) Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 1:47–52

22.

Wang L, Lawrence MS, Wan Y et al (2011) SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 26:2497–2506CrossRef

23.

Fabbri G, Rasi S, Rossi D et al (2011) Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 7:1389–1401CrossRef

24.

Rozman C, Montserrat E (1995) Chronic lymphocytic leukemia. N Engl J Med 16:1052–1057CrossRef

25.

Zenz T, Mertens D, Kuppers R et al (2010) From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 1:37–50

26.

Hamblin TJ, Davis Z, Gardiner A et al (1999) Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 6:1848–1854

27.

Kan Z, Jaiswal BS, Stinson J et al (2010) Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 7308:869–873CrossRef

28.

Grabher C, von Boehmer H, Look AT (2006) Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer 5:347–359CrossRef

29.

Weng AP, Ferrando AA, Lee W et al (2004) Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 5694:269–271CrossRef

30.

Palomero T, Lim WK, Odom DT et al (2006) NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci USA 48:18261–18266CrossRef

31.

Tsimberidou AM, Keating MJ (2006) Richter’s transformation in chronic lymphocytic leukemia. Semin Oncol 2:250–256CrossRef

32.

Kanai M, Hanashiro K, Kim SH et al (2007) Inhibition of Crm1-p53 interaction and nuclear export of p53 by poly(ADP-ribosyl)ation. Nat Cell Biol 10:1175–1183CrossRef

33.

Wang W, Budhu A, Forgues M et al (2005) Temporal and spatial control of nucleophosmin by the Ran–Crm1 complex in centrosome duplication. Nat Cell Biol 8:823–830CrossRef

34.

Ranganathan P, Yu X, Na C et al (2012) Pre-clinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood. doi:10.1182/blood-2012-04-423160

35.

O’Neill LA, Bowie AG (2007) The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 5:353–364CrossRef

36.

Ngo VN, Young RM, Schmitz R et al (2011) Oncogenically active MYD88 mutations in human lymphoma. Nature 7332:115–119CrossRef

37.

Kroll J, Shi X, Caprioli A et al (2005) The BTB-kelch protein KLHL6 is involved in B-lymphocyte antigen receptor signaling and germinal center formation. Mol Cell Biol 19:8531–8540CrossRef

38.

Dohner H, Stilgenbauer S, Benner A et al (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 26:1910–1916CrossRef

39.

Klein U, Lia M, Crespo M et al (2010) The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 1:28–40CrossRef

40.

Calin GA, Dumitru CD, Shimizu M et al (2002) Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 24:15524–15529CrossRef

41.

Golas MM, Sander B, Will CL et al (2003) Molecular architecture of the multiprotein splicing factor SF3b. Science 5621:980–984CrossRef

42.

Wu L, Multani AS, He H et al (2006) Pot1 deficiency initiates DNA damage checkpoint activation and aberrant homologous recombination at telomeres. Cell 1:49–62CrossRef

43.

Hockemeyer D, Daniels JP, Takai H et al (2006) Recent expansion of the telomeric complex in rodents: two distinct POT1 proteins protect mouse telomeres. Cell 1:63–77CrossRef

44.

Nagarajan P, Onami TM, Rajagopalan S et al (2009) Role of chromodomain helicase DNA-binding protein 2 in DNA damage response signaling and tumorigenesis. Oncogene 8:1053–1062CrossRef

45.

Prazeres H, Torres J, Rodrigues F et al (2011) Chromosomal, epigenetic and microRNA-mediated inactivation of LRP1B, a modulator of the extracellular environment of thyroid cancer cells. Oncogene 11:1302–1317CrossRef

46.

Quesada V, Ramsay AJ, Lopez-Otin C (2012) Chronic lymphocytic leukemia with SF3B1 mutation. N Engl J Med 26:2530CrossRef

47.

Rossi D, Bruscaggin A, Spina V et al (2011) Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 26:6904–6908CrossRef

48.

Yoshida K, Sanada M, Shiraishi Y et al (2011) Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 7367:64–69CrossRef

49.

Graubert TA, Shen D, Ding L et al (2012) Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet 1:53–57

50.

Papaemmanuil E, Cazzola M, Boultwood J et al (2011) Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 15:1384–1395CrossRef

51.

David CJ, Manley JL (2010) Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev 21:2343–2364CrossRef

52.

Folco EG, Coil KE, Reed R (2011) The anti-tumor drug E7107 reveals an essential role for SF3b in remodeling U2 snRNP to expose the branch point-binding region. Genes Dev 5:440–444CrossRef

53.

Corrionero A, Minana B, Valcarcel J (2011) Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A. Genes Dev 5:445–459CrossRef

54.

Chen AA, Marsit CJ, Christensen BC et al (2009) Genetic variation in the vitamin C transporter, SLC23A2, modifies the risk of HPV16-associated head and neck cancer. Carcinogenesis 6:977–981CrossRef

55.

Bulwin GC, Heinemann T, Bugge V et al (2006) TIRC7 inhibits T cell proliferation by modulation of CTLA-4 expression. J Immunol 10:6833–6841

56.

Yu B, Zhou X, Li B et al (2011) FOXP1 expression and its clinicopathologic significance in nodal and extranodal diffuse large B-cell lymphoma. Ann Hematol 6:701–708CrossRef

57.

Brown PJ, Ashe SL, Leich E et al (2008) Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL. Blood 5:2816–2824CrossRef

58.

Garbelli A, Radi M, Falchi F et al (2011) Targeting the human DEAD-box polypeptide 3 (DDX3) RNA helicase as a novel strategy to inhibit viral replication. Curr Med Chem 20:3015–3027CrossRef

59.

Yedavalli VS, Neuveut C, Chi YH et al (2004) Requirement of DDX3 DEAD box RNA helicase for HIV-1 Rev-RRE export function. Cell 3:381–392CrossRef

60.

van der Maarel SM, Scholten IH, Huber I et al (1996) Cloning and characterization of DXS6673E, a candidate gene for X-linked mental retardation in Xq13.1. Hum Mol Genet 7:887–897CrossRef

61.

Xiao S, Nalabolu SR, Aster JC et al (1998) FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat Genet 1:84–87CrossRef

62.

Grenard P, Bates MK, Aeschlimann D (2001) Evolution of transglutaminase genes: identification of a transglutaminase gene cluster on human chromosome 15q15. Structure of the gene encoding transglutaminase X and a novel gene family member, transglutaminase Z. J Biol Chem 35:33066–33078CrossRef

63.

Stratton MR (2011) Exploring the genomes of cancer cells: progress and promise. Science 6024:1553–1558CrossRef

64.

Service RF (2006) Gene sequencing. The race for the $1000 genome. Science 5767:1544–1546CrossRef

65.

Maheswaran S, Sequist LV, Nagrath S et al (2008) Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 4:366–377CrossRef

66.

Leary RJ, Kinde I, Diehl F et al (2010) Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med 20:20ra14

Title: Next-generation sequencing reveals the secrets of the chronic lymphocytic leukemia genome
Authors: Andrew J. Ramsay
Alejandra Martínez-Trillos
Pedro Jares
David Rodríguez
Agnieszka Kwarciak
Víctor Quesada
Publication date: 01-01-2013
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 1/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-012-0922-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

CD44+/CD24− breast cancer cells isolated from MCF-7 cultures exhibit enhanced angiogenic properties

SEOM recommendations on the structure and operation of hereditary cancer genetic counseling units (HCGCUs)

Intra-operative electron beam radiotherapy for newly diagnosed and recurrent malignant gliomas: feasibility and long-term outcomes

Retreatment with radiotherapy for symptomatic bone, brain or visceral metastases

Accuracy and axilla sparing potentials of sentinel lymph node biopsy with methylene blue alone performed before versus after neoadjuvant chemotherapy in breast cancer: a single institution experience

Progressive increase of glucose transporter-3 (GLUT-3) expression in estrogen-induced breast carcinogenesis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer